Literature DB >> 7903279

Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells.

Y Hiromatsu1, M Sato, K Tanaka, N Ishisaka, J Kamachi, K Nonaka.   

Abstract

We investigated the effects of nicotinamide and 3-aminobenzamide (3-AB), inhibitors of poly (ADP ribose) synthetase, on phytohaemagglutinin (PHA)- or interferon-gamma (IFN-gamma)-induced intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells from patients with Graves' disease. Primary cultured thyroid cells were incubated for 3 days with IFN-gamma (10-800 U/ml) or PHA (1-50 micrograms/ml) in the presence of nicotinamide, 3-AB, superoxide dismutase or catalase. The surface expression of ICAM-1 was measured by flow cytometry. Nicotinamide and 3-AB dose-dependently inhibited the induction of ICAM-1 expression by IFN-gamma or PHA on thyroid cells. Neither catalase nor superoxide dismutase, which are free-radical scavengers, inhibited the expression of ICAM-1 on thyroid cells. Our data suggest that the mechanism of the suppression of ICAM-1 expression on thyroid cells by nicotinamide is not likely to be due to the free radical scavenging. Further studies are indicated to elucidate whether the inhibition of ICAM-1 by these drugs may result in the suppression of autoimmune reaction in the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903279      PMCID: PMC1422199     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  Mechanisms of nicotinamide and thymidine protection from alloxan and streptozocin toxicity.

Authors:  S P LeDoux; C R Hall; P M Forbes; N J Patton; G L Wilson
Journal:  Diabetes       Date:  1988-08       Impact factor: 9.461

2.  Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis.

Authors:  Y Uchigata; H Yamamoto; A Kawamura; H Okamoto
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

3.  Expression of an intercellular adhesion molecule, ICAM-1, by human thyroid cells.

Authors:  A P Weetman; S Cohen; M W Makgoba; L K Borysiewicz
Journal:  J Endocrinol       Date:  1989-07       Impact factor: 4.286

4.  Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases.

Authors:  R Q Zheng; E R Abney; B Grubeck-Loebenstein; C Dayan; R N Maini; M Feldmann
Journal:  J Autoimmun       Date:  1990-12       Impact factor: 7.094

5.  Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by niacinamide and 3-aminobenzamide.

Authors:  K Yamada; E Miyajima; K Nonaka
Journal:  Diabetes       Date:  1990-09       Impact factor: 9.461

6.  Induction of murine teratocarcinoma cell differentiation by suppression of poly(ADP-ribose) synthesis.

Authors:  Y Ohashi; K Ueda; O Hayaishi; K Ikai; O Niwa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy.

Authors:  Y Hiromatsu; H Fukazawa; F Guinard; M Salvi; J How; J R Wall
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

8.  Participation of poly(ADP-ribosyl)ation in the depression of RNA synthesis caused by treatment of mouse lymphoma cells with methylnitrosourea.

Authors:  T Taniguchi; M Agemori; I Kameshita; M Nishikimi; Y Shizuta
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

9.  Induction of human thyroid cell ICAM-1 (CD54) antigen expression and ICAM-1-mediated lymphocyte binding.

Authors:  A Martin; G K Huber; T F Davies
Journal:  Endocrinology       Date:  1990-08       Impact factor: 4.736

10.  Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. An observation in nonobese diabetic (NOD) mice.

Authors:  K Yamada; K Nonaka; T Hanafusa; A Miyazaki; H Toyoshima; S Tarui
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

View more
  9 in total

1.  Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia.

Authors:  A Soop; J Albert; E Weitzberg; A Bengtsson; C-G Nilsson; A Sollevi
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

Review 2.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

3.  Nicotinamide is a potent inhibitor of proinflammatory cytokines.

Authors:  J S Ungerstedt; M Blömback; T Söderström
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 4.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

Review 5.  Graves' ophthalmopathy: state of the art and perspectives.

Authors:  L Bartalena; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

6.  Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes.

Authors:  Prakash Manikwar; Bimo A Tejo; Heather Shinogle; David S Moore; Tahl Zimmerman; Francisco Blanco; Teruna J Siahaan
Journal:  Theranostics       Date:  2011-05-10       Impact factor: 11.556

7.  Potential effects of the combination of nicotinamide, vitamin B2 and vitamin C on oxidative-mediated hepatotoxicity induced by thioacetamide.

Authors:  Samir A E Bashandy; Hossam Ebaid; Sherif A Abdelmottaleb Moussa; Ibrahim M Alhazza; Iftekhar Hassan; Abdulaziz Alaamer; Jameel Al Tamimi
Journal:  Lipids Health Dis       Date:  2018-02-14       Impact factor: 3.876

8.  1-Methylnicotinamide and nicotinamide: two related anti-inflammatory agents that differentially affect the functions of activated macrophages.

Authors:  Rafał Biedroń; Marta Ciszek; Marianna Tokarczyk; Małgorzata Bobek; Maria Kurnyta; Ewa M Słominska; Ryszard T Smoleński; Janusz Marcinkiewicz
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

Review 9.  Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.

Authors:  Noemi Rotllan; Mercedes Camacho; Mireia Tondo; Elena M G Diarte-Añazco; Marina Canyelles; Karen Alejandra Méndez-Lara; Sonia Benitez; Núria Alonso; Didac Mauricio; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Josep Julve
Journal:  Antioxidants (Basel)       Date:  2021-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.